| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $83.4M | +3.6% | -0.8% |
| R&D Expense | $2.5M | -26.9% | -62.6% |
| SG&A Expense | $14.4M | -17.7% | +13.3% |
| Operating Income | $3.6M | +533.9% | -70.9% |
| Pre-tax Income | -$3.2M | +48.1% | -138.8% |
| Net Income | $11.4M | +50.6% | -33.4% |
| EPS (Basic) | $0.05 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $29.9M | +2.3% | +47.2% |
| Accounts Receivable | $31.1M | +7.0% | -21.4% |
| Current Assets | $122.8M | -0.6% | +0.1% |
| Total Assets | $916.7M | +1.2% | +10.3% |
| Current Liabilities | $83.5M | -15.0% | -14.7% |
| Long-term Debt |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $40.0M | — | — |
| Capital Expenditures | $60.9M | — | — |
| Investing Cash Flow | -$69.9M | — | — |
| Financing Cash Flow | $35.0M | — | — |
| Free Cash Flow | -$20.9M | — | — |
| +66.7% |
| -44.4% |
| EPS (Diluted) | $0.05 | +66.7% | -44.4% |
| $351.2M |
| +5.9% |
| +38.9% |
| Total Liabilities | $434.0M | +0.4% | +20.1% |
| Stockholders' Equity | $7.5M | +129.9% | +104.2% |